



Press Release

Thursday, May 21, 2015

Strides Arcolab Limited

Strides House, Bannerghatta Road,
Bangalore – 560076.

Strides inks agreements to acquire a generic pharmaceutical business in Australia and related assets from Aspen for approximately A\$380 million

Acquisition to be EPS accretive immediately

Bangalore, May 21, 2015 – Strides Arcolab (BSE: 532531, NSE: STAR) today announced that Strides Pharma Global Pte. Ltd, Singapore and Strides (Australia) Pharma Pty Ltd, Australia, both wholly owned subsidiaries of Strides Arcolab have signed definitive agreements with certain wholly owned subsidiaries of Aspen Pharmacare Holdings Limited, a company listed on the Johannesburg Stock Exchange (Aspen), to acquire a generic pharmaceutical business in Australia together with certain branded pharmaceutical assets.

The business and assets being acquired from Aspen have a current prescription market share that will rank Strides and its group entities as one of the top 3 generic pharmaceutical suppliers in Australia and among the top 10 pharmaceutical companies in the Australian pharma market.

The business, which will operate under the Arrow Pharmaceuticals brand, will sell approximately 140 generic prescription drugs and an extensive range of non-prescription pharmacy products. The business and the assets being acquired will give Strides group one of the largest pharmaceutical product portfolios in the Australian market.

Strides' previous business in the Australian generic pharmaceutical market, Ascent Pharmahealth Ltd, was sold to Actavis in January 2012 after a successful 5-year investment and growth strategy. The new Arrow Pharmaceuticals business will be led by Dennis Bastas, the previous founder and CEO of Ascent Pharmahealth Ltd.

"The Australian generic pharmaceutical market has always been very successful for Strides. The Aspen Australian generic pharmaceutical assets are a valuable and unique platform for Strides to re-build its business in Australia. Strong local management, a market leading product portfolio supported by our in-house cost effective manufacturing, will be the key ingredients of our strategy for Australia," said Arun Kumar, Founder and Group CEO of Strides Arcolab.



The acquired products had sales of approximately A\$120 million in the past financial year (June 2014) with an EBITDA margin of approximately 31%. The consideration for the acquisitions will be approximately A\$380 million. The acquisition of the business will include access to the product pipeline that was under development by Aspen and includes a number of major product launches in the next six months.

The transactions will be financed by a combination of internal accruals and debt financing. It will be EPS accretive immediately.

The transactions are expected to close by the end of Q2 FY16 subject to customary closing conditions and regulatory approvals.

Investor meet

Strides will announce its full year results on May 22, 2015. Strides will be hosting an investor / analyst meet at 11:30 a.m. on May 25, 2015 at The Trident, Bandra Kurla, Mumbai, to discuss the FY 15 results, the transactions and introduce the Australian leadership team.

About Strides Arcolab Limited:

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical Company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products. The Company has 8 manufacturing facilities and presence in more than 75 countries in developed and emerging markets. Additional information is available at the Company's website at www.stridesarco.com.

For further information, please contact:

<u>Strides</u>	<u>PR Consultancy</u>
Badree Komandur, CFO +91 80 6784 0747	Fortuna PR K Srinivas Reddy: +91 9000527213 srinivas@fortunapr.com
Vikesh Kumar +91 80 6784 0827 Kannan. N: +91 98450 54745 Sandeep Baid: +91 80 6784 0791	K Priya: +91 9535425418 priya@fortunapr.com

